The Anti-Diabetes Drugs market in G20 countries has been growing steadily over the past few years.
Customer preferences: Customers in G20 countries are increasingly becoming health-conscious and are taking steps to prevent and manage diabetes. This has led to a rise in demand for anti-diabetes drugs. Additionally, the aging population in many G20 countries has contributed to the growth of the market as older individuals are more likely to develop diabetes.
Trends in the market: The trends in the Anti-Diabetes Drugs market vary across G20 countries. In the United States, the market is dominated by a few large pharmaceutical companies that have developed innovative drugs. In contrast, the market in China is more fragmented, with many local players producing generic drugs. India is also a major player in the anti-diabetes drug market, with a focus on producing low-cost generic drugs.
Local special circumstances: In Japan, the government has implemented a national health insurance system that covers the cost of anti-diabetes drugs for all citizens. This has led to a high level of demand for these drugs in Japan. In Brazil, the government has implemented a program that provides free anti-diabetes drugs to low-income individuals, which has helped to increase access to these drugs.
Underlying macroeconomic factors: The Anti-Diabetes Drugs market in G20 countries is influenced by several macroeconomic factors. The rising prevalence of diabetes, particularly in developing countries, is a key driver of the market. Additionally, the increasing aging population in many G20 countries is contributing to the growth of the market. Economic growth and increasing disposable incomes are also factors that are driving the market, as individuals are more able to afford these drugs. However, the market is also affected by regulatory factors, such as government policies on drug pricing and reimbursement. The ongoing COVID-19 pandemic has also had an impact on the market, with disruptions to supply chains and changes in healthcare priorities.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
